NO301049B1 - Fremgangsmåte for fremstilling av en plasterformulering med höyt innhold av mykgjörende stoffer - Google Patents
Fremgangsmåte for fremstilling av en plasterformulering med höyt innhold av mykgjörende stoffer Download PDFInfo
- Publication number
- NO301049B1 NO301049B1 NO912466A NO912466A NO301049B1 NO 301049 B1 NO301049 B1 NO 301049B1 NO 912466 A NO912466 A NO 912466A NO 912466 A NO912466 A NO 912466A NO 301049 B1 NO301049 B1 NO 301049B1
- Authority
- NO
- Norway
- Prior art keywords
- active substance
- adhesive
- layer
- weight
- substance
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 6
- 238000009472 formulation Methods 0.000 title claims description 5
- 238000004519 manufacturing process Methods 0.000 title claims description 5
- 239000004033 plastic Substances 0.000 title 1
- 229920003023 plastic Polymers 0.000 title 1
- 239000004014 plasticizer Substances 0.000 title 1
- 239000013543 active substance Substances 0.000 claims abstract description 64
- 239000000853 adhesive Substances 0.000 claims abstract description 41
- 230000001070 adhesive effect Effects 0.000 claims abstract description 41
- 229920000058 polyacrylate Polymers 0.000 claims abstract description 27
- 239000010410 layer Substances 0.000 claims abstract description 26
- 239000012790 adhesive layer Substances 0.000 claims abstract description 13
- 230000000699 topical effect Effects 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 23
- 239000007788 liquid Substances 0.000 claims description 22
- 239000011159 matrix material Substances 0.000 claims description 20
- 239000000126 substance Substances 0.000 claims description 15
- 230000035515 penetration Effects 0.000 claims description 14
- 229920000642 polymer Polymers 0.000 claims description 14
- -1 phthalic acid ester Chemical class 0.000 claims description 11
- LVYLCBNXHHHPSB-UHFFFAOYSA-N 2-hydroxyethyl salicylate Chemical compound OCCOC(=O)C1=CC=CC=C1O LVYLCBNXHHHPSB-UHFFFAOYSA-N 0.000 claims description 10
- SOGAXMICEFXMKE-UHFFFAOYSA-N Butylmethacrylate Chemical compound CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 claims description 10
- KVYGGMBOZFWZBQ-UHFFFAOYSA-N benzyl nicotinate Chemical compound C=1C=CN=CC=1C(=O)OCC1=CC=CC=C1 KVYGGMBOZFWZBQ-UHFFFAOYSA-N 0.000 claims description 8
- 239000011505 plaster Substances 0.000 claims description 8
- 239000004753 textile Substances 0.000 claims description 8
- XILVEPYQJIOVNB-UHFFFAOYSA-N 2-[3-(trifluoromethyl)anilino]benzoic acid 2-(2-hydroxyethoxy)ethyl ester Chemical compound OCCOCCOC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 XILVEPYQJIOVNB-UHFFFAOYSA-N 0.000 claims description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 7
- 229960001493 etofenamate Drugs 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 claims description 6
- 239000000006 Nitroglycerin Substances 0.000 claims description 6
- 229960003711 glyceryl trinitrate Drugs 0.000 claims description 6
- 239000012528 membrane Substances 0.000 claims description 6
- 239000011241 protective layer Substances 0.000 claims description 6
- 229920005989 resin Polymers 0.000 claims description 6
- 239000011347 resin Substances 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 5
- 229960002389 glycol salicylate Drugs 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 229950004580 benzyl nicotinate Drugs 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000004744 fabric Substances 0.000 claims description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 4
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 claims description 3
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 claims description 3
- 239000003435 antirheumatic agent Substances 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 239000005871 repellent Substances 0.000 claims description 3
- 238000007910 systemic administration Methods 0.000 claims description 3
- 238000011200 topical administration Methods 0.000 claims description 3
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 claims description 3
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 claims description 2
- TZZAKSLHHIJRLL-UHFFFAOYSA-N 4-hydroxy-3-methoxybenzamide Chemical compound COC1=CC(C(N)=O)=CC=C1O TZZAKSLHHIJRLL-UHFFFAOYSA-N 0.000 claims description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 2
- 206010016334 Feeling hot Diseases 0.000 claims description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 2
- 229920002845 Poly(methacrylic acid) Polymers 0.000 claims description 2
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- 230000001741 anti-phlogistic effect Effects 0.000 claims description 2
- 239000003974 emollient agent Substances 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 229960001680 ibuprofen Drugs 0.000 claims description 2
- 229960000905 indomethacin Drugs 0.000 claims description 2
- 230000008338 local blood flow Effects 0.000 claims description 2
- 229960002702 piroxicam Drugs 0.000 claims description 2
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims description 2
- 150000003872 salicylic acid derivatives Chemical class 0.000 claims description 2
- 229960001722 verapamil Drugs 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 230000003356 anti-rheumatic effect Effects 0.000 claims 1
- 239000002876 beta blocker Substances 0.000 claims 1
- 229940097320 beta blocking agent Drugs 0.000 claims 1
- 239000000480 calcium channel blocker Substances 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-N o-dicarboxybenzene Natural products OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 claims 1
- 239000004584 polyacrylic acid Substances 0.000 claims 1
- 239000000654 additive Substances 0.000 abstract description 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 42
- 239000011888 foil Substances 0.000 description 15
- 239000000463 material Substances 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 229920001296 polysiloxane Polymers 0.000 description 6
- XBIUWALDKXACEA-UHFFFAOYSA-N 3-[bis(2,4-dioxopentan-3-yl)alumanyl]pentane-2,4-dione Chemical compound CC(=O)C(C(C)=O)[Al](C(C(C)=O)C(C)=O)C(C(C)=O)C(C)=O XBIUWALDKXACEA-UHFFFAOYSA-N 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 238000004132 cross linking Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 4
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- RYSXWUYLAWPLES-MTOQALJVSA-N (Z)-4-hydroxypent-3-en-2-one titanium Chemical compound [Ti].C\C(O)=C\C(C)=O.C\C(O)=C\C(C)=O.C\C(O)=C\C(C)=O.C\C(O)=C\C(C)=O RYSXWUYLAWPLES-MTOQALJVSA-N 0.000 description 2
- BODMYPYTCKYRSP-UHFFFAOYSA-N 1,1-dioctylcyclohexane Chemical compound CCCCCCCCC1(CCCCCCCC)CCCCC1 BODMYPYTCKYRSP-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000002174 Styrene-butadiene Substances 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 239000002313 adhesive film Substances 0.000 description 2
- 239000002998 adhesive polymer Substances 0.000 description 2
- 229920005601 base polymer Polymers 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- MTAZNLWOLGHBHU-UHFFFAOYSA-N butadiene-styrene rubber Chemical compound C=CC=C.C=CC1=CC=CC=C1 MTAZNLWOLGHBHU-UHFFFAOYSA-N 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 150000002314 glycerols Chemical class 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- YNBADRVTZLEFNH-UHFFFAOYSA-N methyl nicotinate Chemical compound COC(=O)C1=CC=CN=C1 YNBADRVTZLEFNH-UHFFFAOYSA-N 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Natural products OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- ZQBAKBUEJOMQEX-UHFFFAOYSA-N phenyl salicylate Chemical compound OC1=CC=CC=C1C(=O)OC1=CC=CC=C1 ZQBAKBUEJOMQEX-UHFFFAOYSA-N 0.000 description 2
- 238000004080 punching Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000011115 styrene butadiene Substances 0.000 description 2
- 229920003048 styrene butadiene rubber Polymers 0.000 description 2
- 229940100640 transdermal system Drugs 0.000 description 2
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- MVQVNTPHUGQQHK-UHFFFAOYSA-N 3-pyridinemethanol Chemical compound OCC1=CC=CN=C1 MVQVNTPHUGQQHK-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- WDJHALXBUFZDSR-UHFFFAOYSA-N Acetoacetic acid Natural products CC(=O)CC(O)=O WDJHALXBUFZDSR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- 229920003151 Eudragit® RL polymer Polymers 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
- 241000208181 Pelargonium Species 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 206010057040 Temperature intolerance Diseases 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960004892 acemetacin Drugs 0.000 description 1
- FSQKKOOTNAMONP-UHFFFAOYSA-N acemetacin Chemical compound CC1=C(CC(=O)OCC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 FSQKKOOTNAMONP-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229960004324 betaxolol Drugs 0.000 description 1
- CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- BQXQGZPYHWWCEB-UHFFFAOYSA-N carazolol Chemical compound N1C2=CC=CC=C2C2=C1C=CC=C2OCC(O)CNC(C)C BQXQGZPYHWWCEB-UHFFFAOYSA-N 0.000 description 1
- 229960004634 carazolol Drugs 0.000 description 1
- 229960003184 carprofen Drugs 0.000 description 1
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 1
- LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 description 1
- 229960001222 carteolol Drugs 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- WOWBFOBYOAGEEA-UHFFFAOYSA-N diafenthiuron Chemical compound CC(C)C1=C(NC(=S)NC(C)(C)C)C(C(C)C)=CC(OC=2C=CC=CC=2)=C1 WOWBFOBYOAGEEA-UHFFFAOYSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229960000920 dihydrocodeine Drugs 0.000 description 1
- RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 description 1
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical class O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 230000008543 heat sensitivity Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 1
- 229960001410 hydromorphone Drugs 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
- 229960000201 isosorbide dinitrate Drugs 0.000 description 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
- 229960003827 isosorbide mononitrate Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- USSIQXCVUWKGNF-QGZVFWFLSA-N levomethadone Chemical compound C=1C=CC=CC=1C(C[C@@H](C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-QGZVFWFLSA-N 0.000 description 1
- 229960002710 levomethadone Drugs 0.000 description 1
- 229960004400 levonorgestrel Drugs 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- WYHUWFDCOJZMPO-UHFFFAOYSA-N methyl 2-methylprop-2-enoate;hydrochloride Chemical compound Cl.COC(=O)C(C)=C WYHUWFDCOJZMPO-UHFFFAOYSA-N 0.000 description 1
- XLFWDASMENKTKL-UHFFFAOYSA-N molsidomine Chemical compound O1C(N=C([O-])OCC)=C[N+](N2CCOCC2)=N1 XLFWDASMENKTKL-UHFFFAOYSA-N 0.000 description 1
- 229960004027 molsidomine Drugs 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- DNKKLDKIFMDAPT-UHFFFAOYSA-N n,n-dimethylmethanamine;2-methylprop-2-enoic acid Chemical compound CN(C)C.CC(=C)C(O)=O.CC(=C)C(O)=O DNKKLDKIFMDAPT-UHFFFAOYSA-N 0.000 description 1
- NPAGDVCDWIYMMC-IZPLOLCNSA-N nandrolone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 NPAGDVCDWIYMMC-IZPLOLCNSA-N 0.000 description 1
- 229960004719 nandrolone Drugs 0.000 description 1
- 239000000025 natural resin Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- RGOVYLWUIBMPGK-UHFFFAOYSA-N nonivamide Chemical compound CCCCCCCCC(=O)NCC1=CC=C(O)C(OC)=C1 RGOVYLWUIBMPGK-UHFFFAOYSA-N 0.000 description 1
- 229960001652 norethindrone acetate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- BARWIPMJPCRCTP-CLFAGFIQSA-N oleyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC BARWIPMJPCRCTP-CLFAGFIQSA-N 0.000 description 1
- 229960002085 oxycodone Drugs 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229960000969 phenyl salicylate Drugs 0.000 description 1
- 150000003021 phthalic acid derivatives Chemical class 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229960002508 pindolol Drugs 0.000 description 1
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920006267 polyester film Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920002959 polymer blend Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
- 229960001289 prazosin Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000003542 rubefacient Substances 0.000 description 1
- 229960000581 salicylamide Drugs 0.000 description 1
- 229940058287 salicylic acid derivative anticestodals Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 description 1
- 229960001693 terazosin Drugs 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 229960004605 timolol Drugs 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7076—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising ingredients of undetermined constitution or reaction products thereof, e.g. rosin or other plant resins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/58—Adhesives
- A61L15/585—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Materials Engineering (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Botany (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
- Road Signs Or Road Markings (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Developing Agents For Electrophotography (AREA)
- Laminated Bodies (AREA)
- Tea And Coffee (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4020144A DE4020144A1 (de) | 1990-06-25 | 1990-06-25 | Pflaster mit hohem gehalt an weichmachenden inhaltsstoffen |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO912466D0 NO912466D0 (no) | 1991-06-24 |
| NO912466L NO912466L (no) | 1991-12-27 |
| NO301049B1 true NO301049B1 (no) | 1997-09-08 |
Family
ID=6409004
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO912466A NO301049B1 (no) | 1990-06-25 | 1991-06-24 | Fremgangsmåte for fremstilling av en plasterformulering med höyt innhold av mykgjörende stoffer |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US5306503A (fr) |
| EP (1) | EP0464573B1 (fr) |
| JP (1) | JP2700362B2 (fr) |
| AT (1) | ATE164769T1 (fr) |
| CA (1) | CA2045290C (fr) |
| DE (2) | DE4020144A1 (fr) |
| DK (1) | DK0464573T3 (fr) |
| ES (1) | ES2116989T3 (fr) |
| FI (1) | FI111338B (fr) |
| IE (1) | IE912181A1 (fr) |
| NO (1) | NO301049B1 (fr) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW221970B (fr) * | 1991-06-26 | 1994-04-01 | Tbs Lab Inc | |
| DE4229230C2 (de) * | 1992-09-02 | 1997-01-16 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit Pentetrazol als Wirkstoff |
| DE4336557C2 (de) * | 1993-05-06 | 1997-07-17 | Lohmann Therapie Syst Lts | Estradiolhaltiges transdermales therapeutisches System, Verfahren zu seiner Herstellung und seine Verwendung |
| DE4333595A1 (de) * | 1993-10-01 | 1995-04-06 | Labtec Gmbh | Transdermales therapeutisches System zur Applikation von Arzneimitteln auf die Haut |
| DE4403487C2 (de) * | 1994-02-04 | 2003-10-16 | Lohmann Therapie Syst Lts | Arznei-Pflaster mit UV-vernetzbaren Acrylat-Copolymeren |
| DE4406332C1 (de) * | 1994-02-28 | 1995-06-22 | Sanol Arznei Schwarz Gmbh | Pharmazeutische Verwendung von Nitroglycerin zur Verhinderung unerwünschter Wehentätigkeit bei Säugern in einer transdermalen Applikationsform |
| FR2719770A1 (fr) * | 1994-05-11 | 1995-11-17 | Lhd Lab Hygiene Dietetique | Système matriciel pour administration transdermique d'ibuprofène et procédé de préparation. |
| NZ293849A (en) * | 1994-09-14 | 1998-10-28 | Minnesota Mining & Mfg | Transdermal delivery matrix comprising a macromonomer containing acrylate or metacrylate copolymer, a softener and a drug |
| AU6032696A (en) * | 1995-06-07 | 1996-12-30 | Cygnus Therapeutic Systems | Pressure sensitive acrylate adhesive composition cross-linke d with aluminum acetylacetonate and containing a drug having a reactive aromatic hydroxyl group |
| DE19526864A1 (de) * | 1995-07-22 | 1997-01-23 | Labtec Gmbh | Hormonpflaster |
| US8084051B1 (en) * | 1995-11-13 | 2011-12-27 | Bio Med Sciences, Inc. | Therapeutic medical garments with silicone sheeting component for scar treatment, process of manufacture and use |
| DE19650471A1 (de) * | 1996-12-05 | 1998-06-10 | Beiersdorf Ag | Wirkstoffhaltige Pflaster |
| DE19653606A1 (de) * | 1996-12-20 | 1998-06-25 | Roehm Gmbh | Haft- und Bindemittel aus (Meth)acrylatpolymer, organischer Säure und Weichmacher |
| DE19700913C2 (de) | 1997-01-14 | 2001-01-04 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System zur Abgabe von Hormonen |
| DE19706824C1 (de) * | 1997-02-21 | 1998-03-26 | Lohmann Therapie Syst Lts | Transdermales oder topisches Plastersystem mit Polyacrylatmatrix mit verbesserten physikalischen Eigenschaften |
| US5968547A (en) * | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
| DE19830651A1 (de) * | 1998-07-09 | 2000-01-13 | Lohmann Therapie Syst Lts | Steroidhaltiges Pflaster, Verfahren zu seiner Herstellung und Verwendung |
| DE19830649C2 (de) * | 1998-07-09 | 2003-04-10 | Lohmann Therapie Syst Lts | Topisches Pflaster mit nichtsteroidalen Antirheumatika mit Säuregruppe |
| DE19834496B4 (de) * | 1998-07-31 | 2004-02-26 | Beiersdorf Ag | Verbesserte Freisetzung von Ibuprofen aus Heißschmelzklebemassen in wirkstoffhaltigen Pflastern durch Zusatz von pharmazeutischen Hilfsstoffen und Verwendung von Hilfsstoffen zur Verbesserung der Freisetzung von Ibuprofen |
| US6475514B1 (en) * | 1998-12-03 | 2002-11-05 | Andrew Blitzer | Athletic patch |
| ES2237415T5 (es) * | 1999-01-14 | 2008-12-16 | Noven Pharmaceuticals, Inc. | Composiciones dermicas. |
| US20030170195A1 (en) * | 2000-01-10 | 2003-09-11 | Noven Pharmaceuticals, Inc. | Compositions and methods for drug delivery |
| PT1150661E (pt) * | 1999-02-05 | 2004-02-27 | Cipla Ltd | Produto para pulverizacao para aplicacao topica |
| DE19911262C2 (de) * | 1999-03-13 | 2003-04-10 | Scs Skin Care Systems Gmbh | Vorrichtung zur Abgabe kosmetischer Wirkstoffe |
| DE19923427A1 (de) * | 1999-05-21 | 2000-11-23 | Lohmann Therapie Syst Lts | Vorrichtung und Verfahren zur Steigerung der transdermalen Permeation von Arzneistoffen |
| DE19940238A1 (de) | 1999-08-25 | 2001-03-01 | Lohmann Therapie Syst Lts | Wirkstoffhaltiges therapeutisches System zur Applikation auf der Haut mit mindestens zwei polymerhaltigen Schichten |
| US6168028B1 (en) | 1999-11-19 | 2001-01-02 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Packaged skin product |
| DE10032537A1 (de) * | 2000-07-05 | 2002-01-31 | Labtec Gmbh | Dermales System, enthaltend 2-(3-Benzophenyl)Propionsäure |
| DE10049225A1 (de) * | 2000-09-28 | 2002-04-11 | Labtec Gmbh | Dermales System, enthaltend Diclofenac |
| WO2002045701A2 (fr) * | 2000-12-05 | 2002-06-13 | Noven Pharmaceuticals, Inc. | Inhibition de la cristallisation de medicament dans des systemes d'administration transdermique et procedes d'utilisation |
| DE10060550C1 (de) * | 2000-12-06 | 2002-04-18 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit dem Wirkstoff Oxybutynin und Verfahren zur Herstellung Oxybutynin enthaltender Wirkstoffschichten |
| DE10103860B4 (de) * | 2001-01-30 | 2004-12-23 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System für die Verabreichung carboxylgruppenhaltiger, nichtsteroidaler Antiphlogistika, sowie Verfahren zu seiner Herstellung |
| DE10121471A1 (de) * | 2001-05-02 | 2002-11-07 | Beiersdorf Ag | Oberflächendotierte wirkstoffhaltige Pflaster |
| US20050100588A1 (en) * | 2001-06-13 | 2005-05-12 | Beiersdorf Ag | Self-adhesive matrix plaster containing an active ingredient and based on polyurethane gels |
| NZ542887A (en) * | 2003-04-08 | 2008-05-30 | Algorx Pharmaceuticals Inc | Preparation and purification of synthetic capsaicin |
| PE20081297A1 (es) * | 2003-04-30 | 2008-09-17 | Purdue Pharma Lp | Forma de dosificacion transdermica resistente a la manipulacion |
| US8790689B2 (en) | 2003-04-30 | 2014-07-29 | Purdue Pharma L.P. | Tamper resistant transdermal dosage form |
| CN101119713A (zh) * | 2004-11-24 | 2008-02-06 | 阿尔高克斯制药公司 | 类辣椒素凝胶制剂及其用途 |
| ITMI20050084A1 (it) * | 2005-01-21 | 2006-07-22 | Biofarmitalia Spa | Tessuto composito flessibile traspirante formato da strati di materiale tessile separati e tra di loro accoppiati da uno strato di polimero adesivo |
| DK2120896T3 (en) * | 2007-01-11 | 2017-09-11 | Drossapharm Ag | MEDICAL ACTIVE PLASTER |
| CN102933207B (zh) | 2009-10-30 | 2018-02-02 | Ix生物医药有限公司 | 快速溶解固体剂型 |
| DE102012000369A1 (de) | 2012-01-11 | 2013-07-11 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Transdermales therapeutisches System mit Cholinesterase-Hemmer |
| US20140083878A1 (en) * | 2012-09-21 | 2014-03-27 | Mylan Inc. | Transdermal drug delivery device |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5843368B2 (ja) * | 1980-10-30 | 1983-09-27 | 日東電工株式会社 | 消炎鎮痛貼付剤 |
| JPS5910513A (ja) * | 1982-07-12 | 1984-01-20 | Nitto Electric Ind Co Ltd | 医薬製剤 |
| JPS60123417A (ja) * | 1983-12-07 | 1985-07-02 | Nitto Electric Ind Co Ltd | 薬物投与部材 |
| WO1985003878A1 (fr) * | 1984-03-01 | 1985-09-12 | Sandoz Ag | Compositions pharmaceutiques |
| JPS60224638A (ja) * | 1984-04-23 | 1985-11-09 | Kao Corp | 経皮吸収促進剤およびこれを含有する外用剤 |
| JPS60252412A (ja) * | 1984-05-29 | 1985-12-13 | Nichiban Co Ltd | 貼布治療製剤 |
| DE3634016A1 (de) * | 1986-04-17 | 1987-10-29 | Lohmann Gmbh & Co Kg | Flaechenfoermiges therapeutisches system, verfahren zu seiner herstellung und seine verwendung |
| DE3775830D1 (de) * | 1986-06-13 | 1992-02-20 | Alza Corp | Aktivierung eines transdermalen drogenabgabesystems durch feuchtigkeit. |
| DE3629304A1 (de) * | 1986-08-28 | 1988-03-24 | Lohmann Gmbh & Co Kg | Transdermales therapeutisches system, seine verwendung und verfahren zu seiner herstellung |
| JPS63201119A (ja) * | 1987-02-17 | 1988-08-19 | Kao Corp | 貼付剤組成物 |
| DE3714140A1 (de) * | 1987-04-28 | 1988-11-10 | Lohmann Therapie Syst Lts | Wirkstoffhaltiges pflaster zur kontrollierten verabreichung von wirkstoffen an die haut, seine verwendung sowie verfahren zur gesteuerten verabreichung von wirkstoffen an die haut |
| US4956181A (en) * | 1987-05-08 | 1990-09-11 | Eastman Kodak | Nitrate therapy for angina pectoris |
| DE3743946A1 (de) * | 1987-09-01 | 1989-03-09 | Lohmann Gmbh & Co Kg | Vorrichtung zur abgabe von nitroglycerin an die haut, verfahren zu ihrer herstellung sowie ihre verwendung |
| US4994267A (en) * | 1988-03-04 | 1991-02-19 | Noven Pharmaceuticals, Inc. | Transdermal acrylic multipolymer drug delivery system |
| DE3807283A1 (de) * | 1988-03-05 | 1989-09-14 | Basf Ag | Verfahren zur herstellung eines pflasters zur transdermalen anwendung pharmazeutischer wirkstoffe |
| DE3843239C1 (fr) * | 1988-12-22 | 1990-02-22 | Lohmann Therapie Syst Lts | |
| DE3843238C1 (fr) * | 1988-12-22 | 1990-02-22 | Lohmann Therapie Syst Lts | |
| DE3901551A1 (de) * | 1989-01-20 | 1990-07-26 | Lohmann Therapie Syst Lts | Superfizielles therapeutisches system mit einem gehalt an einem antineoplastischen wirkstoff, insbesondere 5-fluoruracil |
-
1990
- 1990-06-25 DE DE4020144A patent/DE4020144A1/de active Granted
-
1991
- 1991-06-21 US US07/718,668 patent/US5306503A/en not_active Expired - Lifetime
- 1991-06-24 JP JP3151275A patent/JP2700362B2/ja not_active Expired - Lifetime
- 1991-06-24 DE DE59108962T patent/DE59108962D1/de not_active Expired - Lifetime
- 1991-06-24 IE IE218191A patent/IE912181A1/en not_active IP Right Cessation
- 1991-06-24 ES ES91110409T patent/ES2116989T3/es not_active Expired - Lifetime
- 1991-06-24 AT AT91110409T patent/ATE164769T1/de not_active IP Right Cessation
- 1991-06-24 EP EP91110409A patent/EP0464573B1/fr not_active Expired - Lifetime
- 1991-06-24 DK DK91110409T patent/DK0464573T3/da active
- 1991-06-24 CA CA002045290A patent/CA2045290C/fr not_active Expired - Lifetime
- 1991-06-24 NO NO912466A patent/NO301049B1/no not_active IP Right Cessation
- 1991-06-24 FI FI913072A patent/FI111338B/fi not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DE4020144A1 (de) | 1992-01-09 |
| FI913072A0 (fi) | 1991-06-24 |
| US5306503A (en) | 1994-04-26 |
| EP0464573A1 (fr) | 1992-01-08 |
| DE4020144C2 (fr) | 1993-07-29 |
| JPH04230212A (ja) | 1992-08-19 |
| JP2700362B2 (ja) | 1998-01-21 |
| NO912466L (no) | 1991-12-27 |
| NO912466D0 (no) | 1991-06-24 |
| EP0464573B1 (fr) | 1998-04-08 |
| CA2045290C (fr) | 2002-02-05 |
| FI111338B (fi) | 2003-07-15 |
| DK0464573T3 (da) | 1999-01-11 |
| IE912181A1 (en) | 1992-01-01 |
| ATE164769T1 (de) | 1998-04-15 |
| FI913072A (fi) | 1991-12-26 |
| CA2045290A1 (fr) | 1991-12-26 |
| ES2116989T3 (es) | 1998-08-01 |
| DE59108962D1 (de) | 1998-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO301049B1 (no) | Fremgangsmåte for fremstilling av en plasterformulering med höyt innhold av mykgjörende stoffer | |
| US6153216A (en) | Transdermal estradiol/progestogen agent patch and its production | |
| ES2237415T5 (es) | Composiciones dermicas. | |
| ES2626784T3 (es) | Dispositivo de administración transdérmica de fármacos | |
| JP3523259B2 (ja) | 溶媒なしに製造できる揮発性活性物質を含有するプラスター | |
| JP2014196327A (ja) | 薬物送達を変更する多層接着マトリックスを含有する経皮的システム | |
| CA2896336C (fr) | Compositions et procedes pour l'administration transdermique d'agents anti-inflammatoires non steroidiens | |
| TWI710381B (zh) | 經皮吸收製劑 | |
| NZ309980A (en) | Transdermal composition containing a blend of one or more polymers, one or more drugs that has a low molecular weight and is liquid at room temperature | |
| NO180107B (no) | Fremgangsmåte for fremstilling av et transdermalt terapeutisk system med physostigmin som virkestoff | |
| CA2376291A1 (fr) | Sparadrap et embllage pour sparadrap | |
| JP2006241179A (ja) | 粘着剤及び貼付剤 | |
| NO311404B1 (no) | Plaster for transdermal administrering av flyktige, farmasöytisk aktive, kjemisk basiske bestanddeler, samtfremgangsmåte for fremstilling av plasteret | |
| WO2017048595A1 (fr) | Système d'administration transdermique | |
| FI118885B (fi) | Skopolamiinilaastari | |
| JPS6393714A (ja) | 経皮吸収貼付剤 | |
| WO2007009320A1 (fr) | Préparation de statines pour libération prolongée | |
| CA2407854C (fr) | Systeme therapeutique occlusif pourvu d'une couche dorsale non occlusive | |
| JP2003511408A (ja) | アセチルサリチル酸および／またはサリチル酸投与用の経皮治療システム | |
| JP2011225536A (ja) | 貼付製剤およびその製造方法 | |
| CN109394735A (zh) | 具有高溶解度的布洛芬或其结构类似物经皮给药系统 | |
| JP3098095B2 (ja) | 透湿性支持体を用いた貼付剤 | |
| CA3236288A1 (fr) | Platre occlusif a support flexible | |
| KR20080006961A (ko) | 비스테로이드성 소염진통제의 경피 투여 제제 및 그제조방법 | |
| JPH03120213A (ja) | 経皮吸収製剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |